119th Congress · introduced in the House · Feb 4, 2025
United States Trade Leadership in the Indo-Pacific Act
Official title from Congress.gov
Latest action (Feb 4, 2025): Referred to the House Committee on Ways and Means.
View on Congress.govPolicy area: Foreign Trade and International Finance
Congressional Research Service summary, version: Introduced in House (Feb 4, 2025)
United States Trade Leadership in the Indo-Pacific Act
This bill requires certain actions related to trade in the Indo-Pacific region.
Specifically, the bill directs the U.S. International Trade Commission to investigate the effects of existing Indo-Pacific regional trade agreements (e.g., the Regional Comprehensive Economic Partnership and the Comprehensive and Progressive Agreement for Trans-Pacific Partnership) on U.S. exporters and competitiveness in the region.
Additionally, the bill establishes the Indo-Pacific Trade Strategy Commission to develop findings and recommendations for a comprehensive trade strategy for the Indo-Pacific region.
Includes amendment, cloture, and procedural votes. Each is labeled with its exact question; only a passage question is a vote to pass the bill.
No recorded roll calls on this bill in coverage.
Referred to the House Committee on Ways and Means.
Introduced in House
Introduced in House
Actions from Congress.gov, newest first.
Advisory bodies · Asia · Australia · Bangladesh · Bhutan · Brunei · Burma · Cambodia · China · Competitiveness, trade promotion, trade deficits · Congressional oversight · Fiji · Free trade and trade barriers · Government trust funds · India · Indonesia · Japan · Kiribati · Laos · Malaysia · Maldives · Marshall Islands · Micronesia · Mongolia · Nauru · Nepal · New Zealand · North Korea · Oceania · Palau · Papua New Guinea · Philippines · Samoa · Singapore · Solomon Islands · South Asia · South Korea · Sri Lanka · Supply chain · Taiwan · Thailand · Tonga · Trade agreements and negotiations · Tuvalu · Vanuatu · Vietnam
LD-2 reports whose issue descriptions explicitly cite this bill (bill type and number validated against Congress.gov records). A citation does not establish the client's position or any contact with a member.
Loading lobbying reportsCoverage: reports for 2025 onward, posted Jan 1, 2025 through Oct 24, 2026.
8 citations.
CHAMBER OF COMMERCE OF THE U.S.A. · lobbying firm or registrant: CHAMBER OF COMMERCE OF THE U.S.A.
2025 Q4 report (Oct 1, 2025 – Dec 31, 2025) · posted Jan 20, 2026 · issue area: Foreign Relations
$17,960,000
Spent on own lobbying
H.R. 33/S. 199, United States-Taiwan Expedited Double-Tax Relief Act H.R. 661, MIRACLE Medical Technology Act H.R. 953, United States Trade Leadership in the Indo-Pacific Act H.R. 1743/S. 776, UNITED Act H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2675, Protectin…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
CHAMBER OF COMMERCE OF THE U.S.A. · lobbying firm or registrant: CHAMBER OF COMMERCE OF THE U.S.A.
2025 Q4 report (Oct 1, 2025 – Dec 31, 2025) · posted Jan 20, 2026 · issue area: Trade (domestic/foreign)
$17,960,000
Spent on own lobbying
H.R. 33/S. 199, United States-Taiwan Expedited Double-Tax Relief Act H.R. 953, United States Trade Leadership in the Indo-Pacific Act H.R. 1625, the HELP Extension Act H.R. 1743/S. 776, Undertaking Negotiations on Investment and Trade fo…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
CHAMBER OF COMMERCE OF THE U.S.A. · lobbying firm or registrant: CHAMBER OF COMMERCE OF THE U.S.A.
2025 Q3 report (Jul 1, 2025 – Sep 30, 2025) · posted Oct 20, 2025 · issue area: Trade (domestic/foreign)
$13,650,000
Spent on own lobbying
H.R. 33/S. 199, United States-Taiwan Expedited Double-Tax Relief Act H.R. 953, United States Trade Leadership in the Indo-Pacific Act H.R. 1625, the HELP Extension Act H.R. 1743/S. 776, Undertaking Negotiations on Investment and Trade fo…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
CHAMBER OF COMMERCE OF THE U.S.A. · lobbying firm or registrant: CHAMBER OF COMMERCE OF THE U.S.A.
2025 Q3 report (Jul 1, 2025 – Sep 30, 2025) · posted Oct 20, 2025 · issue area: Foreign Relations
$13,650,000
Spent on own lobbying
H.R. 33/S. 199, United States-Taiwan Expedited Double-Tax Relief Act H.R. 661, MIRACLE Medical Technology Act H.R. 953, United States Trade Leadership in the Indo-Pacific Act H.R. 1743/S. 776, UNITED Act H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2675, Protectin…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
CHAMBER OF COMMERCE OF THE U.S.A. · lobbying firm or registrant: CHAMBER OF COMMERCE OF THE U.S.A.
2025 Q2 report (Apr 1, 2025 – Jun 30, 2025) · posted Jul 21, 2025 · issue area: Foreign Relations
$19,340,000
Spent on own lobbying
H.R. 1, One Big Beautiful Bill Act H.R. 33/S. 199, United States-Taiwan Expedited Double-Tax Relief Act H.R. 661, MIRACLE Medical Technology Act H.R. 953, United States Trade Leadership in the Indo-Pacific Act H.R. 1743/S. 776, UNITED Act S.J. Res. 37, A joint resolution terminating the national emergency declar…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
CHAMBER OF COMMERCE OF THE U.S.A. · lobbying firm or registrant: CHAMBER OF COMMERCE OF THE U.S.A.
2025 Q2 report (Apr 1, 2025 – Jun 30, 2025) · posted Jul 21, 2025 · issue area: Trade (domestic/foreign)
$19,340,000
Spent on own lobbying
H.R. 1, One Big Beautiful Bill Act H.R. 33/S. 199, United States-Taiwan Expedited Double-Tax Relief Act H.R. 953, United States Trade Leadership in the Indo-Pacific Act H.R. 1548/S. 691, Leveling the Playing Field 2.0 Act H.R. 1743/S. 776, Undertaking Negotiations on Inve…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
CHAMBER OF COMMERCE OF THE U.S.A. · lobbying firm or registrant: CHAMBER OF COMMERCE OF THE U.S.A.
2025 Q1 report (Jan 1, 2025 – Mar 31, 2025) · posted Apr 21, 2025 · issue area: Foreign Relations
$19,340,000
Spent on own lobbying
H.R. 33/S. 199, United States-Taiwan Expedited Double-Tax Relief Act H.R. 661, MIRACLE Medical Technology Act H.R. 953, United States Trade Leadership in the Indo-Pacific Act H.R. 1743/S. 776, UNITED Act Draft legislation titled Medical Supply Chain Resilience Act Potential leg…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
CHAMBER OF COMMERCE OF THE U.S.A. · lobbying firm or registrant: CHAMBER OF COMMERCE OF THE U.S.A.
2025 Q1 report (Jan 1, 2025 – Mar 31, 2025) · posted Apr 21, 2025 · issue area: Trade (domestic/foreign)
$19,340,000
Spent on own lobbying
…Expedited Double-Tax Relief Act H.R. 661, Maximizing Israel-U.S. Research Advancement and Collaborative Leadership in Emerging (MIRACLE) Medical Technology Act H.R. 953, United States Trade Leadership in the Indo-Pacific Act H.R. 1743/S. 776, Undertaking Negotiations on Investment and Trade for Economic Dynamism (UNITED) Act S…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing